|
Bellicum Pharmaceuticals Inc (BLCM) |
|
Bellicum Pharmaceuticals Inc
BLCM's Fundamental analysis
Select the Comparisons :
|
|
Select the Ratio:
|
|
|
Bellicum Pharmaceuticals Inc 's sales fell
by -0.89 % in III. Quarter 2023 from the same quarter a year ago.
Ranking at No. 3037
Major Pharmaceutical Preparations industry recorded
deterioration of revenues by -4.76 %
Bellicum Pharmaceuticals Inc net loss decreased from $-7 millions, to $-1 millions in III. Quarter 2023,
• More on BLCM's Growth
|
|
Bellicum Pharmaceuticals Inc realized a net loss in trailing twelve months.
Bellicum Pharmaceuticals Inc realized cash reduction of $ -0.74 per share in trailing twelve-month period. |
Company |
- |
PE TTM
|
Industry |
- |
PE TTM
|
|
Company's Price to Sales ratio is at 1.56.
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.42.
• More on BLCM's Valuation
|
|
|
|
|
Bellicum Pharmaceuticals Inc realized net loss in trailing twelve months.
Bellicum Pharmaceuticals Inc realized cash outflow of $ -0.74per share in trailing twelve-month period. |
Company |
- |
PE TTM
|
Industry |
- |
PE TTM
|
|
Company's Price to Sales ratio is at 1.56.
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.42.
• More on BLCM's Valuation
|
|
|
|
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Copyright © 2025 CSIMarket, Inc. All rights
reserved.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com